Imigran (Sumatriptan)

Sumatriptan acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors, causing constriction of dilated cranial blood vessels and inhibiting the release of neuropeptides that transmit pain signals in the trigeminal pathway.

The appropriate dose of Imigran is determined by a qualified prescriber based on the individual patient's condition, response, and any relevant medical history. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for sumatriptan in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Imigran.

To request Imigran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imigran (sumatriptan) belongs to the triptan class, which is generally more specific for migraine relief than non‑specific analgesics such as NSAIDs. Compared with newer CGRP antagonists, triptans have a longer history of use and are often less expensive, but they carry a higher risk of cardiovascular effects.

Imigran should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Imigran is taken orally, usually as a tablet, with or without water. It is intended for single‑dose use at the onset of a migraine attack; a second dose may be considered after at least two hours if needed, following the prescriber’s guidance.

The most serious risks include serotonin syndrome when combined with other serotonergic drugs, severe coronary vasospasm leading to chest pain or heart attack, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience these symptoms.

Imigran is contraindicated in patients with known coronary artery disease, uncontrolled hypertension, a history of stroke or transient ischemic attack, and those currently taking MAO inhibitors or ergot derivatives. It should also be used with caution in patients with significant liver or kidney impairment.